Capital International Investors Bei Gene, Ltd. Transaction History

Capital International Investors

  • $504 Billion
  • Q3 2024

A detailed history of Capital International Investors transactions in Bei Gene, Ltd. stock. As of the latest transaction made, Capital International Investors holds 6,430,884 shares of BGNE stock, worth $1.25 Billion. This represents 0.29% of its overall portfolio holdings.

Number of Shares
6,430,884
Previous 7,013,568 8.31%
Holding current value
$1.25 Billion
Previous $1 Billion 44.29%
% of portfolio
0.29%
Previous 0.21%

Shares

24 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 13, 2024
SELL
$143.93 - $224.51 $83.9 Million - $131 Million
-582,684 Reduced 8.31%
6,430,884 $1.44 Billion
Q2 2024

Aug 13, 2024
SELL
$129.52 - $174.32 $6.59 Million - $8.87 Million
-50,860 Reduced 0.72%
7,013,568 $1 Billion
Q1 2024

May 14, 2024
BUY
$141.8 - $181.47 $103 Million - $132 Million
727,556 Added 11.48%
7,064,428 $1.1 Billion
Q4 2023

Feb 13, 2024
BUY
$158.67 - $201.58 $45.3 Million - $57.5 Million
285,397 Added 4.72%
6,336,872 $1.14 Billion
Q3 2023

Nov 13, 2023
SELL
$179.87 - $225.13 $43.9 Million - $54.9 Million
-243,924 Reduced 3.87%
6,051,475 $1.09 Billion
Q2 2023

Aug 11, 2023
SELL
$178.3 - $266.78 $48.2 Million - $72.1 Million
-270,200 Reduced 4.12%
6,295,399 $1.12 Billion
Q1 2023

May 15, 2023
SELL
$215.53 - $274.5 $45.7 Million - $58.2 Million
-211,846 Reduced 3.13%
6,565,599 $1.42 Billion
Q4 2022

Feb 14, 2023
BUY
$125.51 - $229.3 $23.4 Million - $42.7 Million
186,203 Added 2.83%
6,777,445 $1.49 Billion
Q3 2022

Nov 14, 2022
SELL
$131.8 - $202.24 $28.1 Million - $43.1 Million
-213,048 Reduced 3.13%
6,591,242 $889 Million
Q2 2022

Aug 15, 2022
SELL
$121.11 - $216.05 $30.4 Million - $54.2 Million
-251,005 Reduced 3.56%
6,804,290 $1.1 Billion
Q1 2022

May 16, 2022
BUY
$146.52 - $269.56 $104 Million - $192 Million
711,396 Added 11.21%
7,055,295 $1.34 Billion
Q4 2021

Feb 14, 2022
BUY
$248.56 - $389.34 $4.97 Million - $7.78 Million
19,980 Added 0.32%
6,343,899 $1.72 Billion
Q3 2021

Nov 15, 2021
BUY
$249.6 - $403.14 $95.9 Million - $155 Million
384,269 Added 6.47%
6,323,919 $2.3 Billion
Q2 2021

Aug 16, 2021
BUY
$292.75 - $367.01 $41.7 Million - $52.3 Million
142,499 Added 2.46%
5,939,650 $2.04 Billion
Q1 2021

May 14, 2021
BUY
$260.64 - $382.12 $112 Million - $164 Million
428,521 Added 7.98%
5,797,151 $2.01 Billion
Q4 2020

Feb 12, 2021
SELL
$221.31 - $316.61 $131 Million - $188 Million
-593,750 Reduced 9.96%
5,368,630 $1.39 Billion
Q3 2020

Nov 13, 2020
BUY
$189.18 - $286.44 $1.69 Million - $2.56 Million
8,945 Added 0.15%
5,962,380 $1.71 Billion
Q2 2020

Aug 14, 2020
BUY
$123.9 - $195.41 $30.6 Million - $48.2 Million
246,826 Added 4.33%
5,953,435 $1.12 Billion
Q1 2020

May 15, 2020
BUY
$121.84 - $173.19 $141 Million - $200 Million
1,155,679 Added 25.39%
5,706,609 $703 Million
Q4 2019

Feb 18, 2020
BUY
$115.78 - $208.34 $116 Million - $208 Million
998,037 Added 28.09%
4,550,930 $754 Million
Q3 2019

Nov 14, 2019
BUY
$120.61 - $148.29 $131 Million - $161 Million
1,082,594 Added 43.82%
3,552,893 $435 Million
Q2 2019

Aug 14, 2019
BUY
$113.99 - $146.86 $71.4 Million - $92 Million
626,368 Added 33.97%
2,470,299 $306 Million
Q1 2019

May 15, 2019
BUY
$122.82 - $151.83 $101 Million - $124 Million
818,425 Added 79.81%
1,843,931 $593 Million
Q4 2018

Feb 14, 2019
BUY
$107.01 - $175.15 $110 Million - $180 Million
1,025,506 New
1,025,506 $144 Million

Others Institutions Holding BGNE

# of Institutions
249
Shares Held
45.3M
Call Options Held
292K
Put Options Held
119K
View Full List

About BeiGene, Ltd.

BGNE Quotes by TradingView
  • Ticker BGNE
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 103,700,000
  • Market Cap $20.1B
  • Description
  • BeiGene, Ltd., a biotechnology company, focuses on discovering, developing, manufacturing, and commercializing various medicines worldwide. Its products include BRUKINSA to treat relapsed/refractory (R/R) mantle cell lymphoma; Tislelizumab to treat R/R classical Hodgkin's lymphoma; REVLIMID to treat multiple myeloma; VIDAZA to treat myelodysplas...
More about BGNE
Track This Portfolio

Track Capital International Investors Portfolio

Follow Capital International Investors and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Capital International Investors, based on Form 13F filings with the SEC.

News

Stay updated on Capital International Investors with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email